BlackRock Health Sciences Term Trust Files Proxy Statement

TL;DR

BlackRock Health Sciences Term Trust filed its proxy statement, no fee required. Shareholders get to vote.

AI Summary

BlackRock Health Sciences Term Trust filed a Definitive Proxy Statement (DEFA14A) on May 16, 2024. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The filing is for the fiscal year ending December 31.

Why It Matters

This filing provides shareholders with important information regarding the company's governance and upcoming decisions, allowing them to make informed voting choices.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain information indicating significant financial or operational risks.

Key Players & Entities

• BlackRock Health Sciences Term Trust (company) — Registrant
• 0001785971 (company) — Central Index Key
• 811-23466 (company) — SEC File Number
• 24956326 (company) — Film Number
• 100 BELLEVUE PARKWAY, WILMINGTON, DE 19809 (company) — Business Address
• 800 882 0052 (company) — Business Phone
• BlackRock Health Sciences Trust II (company) — Former Company Name
• 20190820 (company) — Date of Name Change

FAQ

Key Financial Figures

• $95m — Share repurchases3 Discount management $95m $17.7m program Resources for you and In
• $17.7m — e repurchases3 Discount management $95m $17.7m program Resources for you and In shares

Filing Documents

• d760114ddefa14a.htm (DEFA14A) — 12KB
• g760114g00a01.jpg (GRAPHIC) — 387KB
• g760114g00a02.jpg (GRAPHIC) — 299KB
• 0001193125-24-140658.txt ( ) — 959KB

From the Filing

HEALTH SCIENCES TERM TRUST BLACKROCK HEALTH SCIENCES TERM TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Definitive Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 BLACKROCK HEALTH SCIENCES TERM TRUST (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Your Vote Matters BlackRock Health Sciences Term Trust (NYSE: BMEZ) Defend YOUR Fund, Save YOUR Income Your vote has never mattered more. At BMEZs upcoming annual meeting on June 25, activist hedge fund Saba Capital Management (Saba) is threatening your dependable, income-paying investment by attempting to install its own hand-picked Board nominees and fire BlackRock, the largest closed-end fund manager, as manager of the Fund. If Saba prevails, your Fundand the consistent monthly income you rely onwill be at risk. BlackRock is fighting for YOU. Vote today ONLY on the WHITE proxy card: FOR the BlackRock Board nominees AGAINST Sabas proposal to terminate the investment management agreement with BlackRock ! IMPORTANT: DO NOT RETURN ANY GOLD CARD YOU RECEIVE FROM SABA BMEZ has delivered strong returns for shareholders YOUR Board seeking investments in next-generation health technologies and continues to pay attractive monthly puts YOU first: income BMEZ continues to gain momentum1 Attractive income 13.8% 5.1% 93% 100% Private markets access Return in Q1 Return in 20231 Outperformance of Outperformance 20241 all closed-end funds of peer funds in in Q1 20242 20232 Liquidity at net asset BMEZ has made impressive gains, outperforming its relevant value peers even with its significant allocation to private equity, where valuations have lagged public markets BlackRock expects its momentum to continue, aided by the Share buybacks strong growth potential of private equity as conditions improve Share repurchases3 Discount management $95m $17.7m program Resources for you and In shares repurchased by Generated in shareholder BlackRock at a discount to profits since inception your advisors net asset value Saba overpromises and underperforms. The risks in supporting Saba include: WIDER DISCOUNTS HIGHER FEES RISKY STRATEGIES The funds Saba has Saba raised costs, including Saba forces their funds commandeered now trade at hidden management fees from investments into risky, speculative wider discounts to net asset underlying funds, at both closed- strategies like SPACs, crypto and value since Saba took over end funds Saba took over hedge funds 1. Bloomberg as of 4/30/2024 2. Morningstar data as of 4/30/2024; Peer group reflects the Morningstar Closed-End Health category 3. BlackRock data as of 2/29/2024; Inception as of 1/29/2020 We ask that all shareholders vote on the enclosed WHITE proxy card today to preserve YOUR Fund: Using the WHITE proxy card, your qualified Board unanimously recommends voting FOR the Boards Nominees, who have created value for all shareholders. Using the WHITE proxy card, your Board unanimously recommends voting AGAINST Sabas proposal to terminate the investment management agreement with BlackRock. DO NOT RETURN ANY GOLD CARD SENT TO YOU BY SABA, AS YOUR BLACKROCK VOTE WILL BE VOIDED How do I vote? Vote online Vote by phone Vote by mail Using the website provided By calling the toll-free By completing and on your enclosed WHITE number on your enclosed returning your enclosed proxy card and following WHITE proxy card and WHITE proxy card in the the simple instructions following the simple postage paid envelope instructions provided If you have already sent back the proxy card received from Saba, you can still change your vote by promptly voting on the WHITE proxy card, which will replace the proxy card you previously completed. If you have any questions about the proposals to be voted, please feel free to contact Georgeson LLC (Georgeson), toll free at 1-866-529-4033. Please do NOT send back any gold proxy card you may receive from Saba Important information about the Fund This material is not an advertisement and is intended for existing shareholder use only. This document and the information contained herein relates solely to BlackRock Health Sciences Term Trust (BMEZ). The information contained herein does not relate to, and is not relevant to, any other fund or product sponsored or distributed by BlackRock or any of its affiliates. This document is not an offer to sell any securities and is

View Full Filing

View this DEFA14A filing on SEC EDGAR